Evidence map›Paper›PMID 42380713›Full record

ArticleBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

Zhihua Ran, Yan Chen, Yinglei Miao, Yufang Wang, Xiang Gao, Jie Zhong, Xueli Ding, Chengdang Wang, Xiaolan Zhang, Yijuan Ding and 5 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Zhihua RanShanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, China.
Yan ChenThe Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.
Yinglei MiaoThe First Affiliated Hospital of Kunming Medical University, Kunming, China.
Yufang WangWest China Hospital of Sichuan University, Chengdu, China.
Xiang GaoThe Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Jie ZhongShanghai Jiaotong University School of Medicine Ruijin Hospital, Shanghai, China.
Xueli DingThe Affiliated Hospital of Qingdao University, Qingdao, China.
Chengdang WangThe First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Xiaolan ZhangThe Second Hospital of Hebei Medical University, Shijiazhuang, China.
Yijuan DingThe Renmin Hospital of Wuhan University, Wuhan, China.
Naizhong HuThe First Affiliated Hospital of Anhui Medical University, Hefei, China.
Dan TangEli Lilly and Company, Shanghai, China.
Jiao YuEli Lilly and Company, Shanghai, China.
Chenxi QianEli Lilly and Company, Shanghai, China.
Jun ShenSchool of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China. shenjun@vip.163.com.ORCID http://orcid.org/0000-0001-7206-1847

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42380713
PMCPMC13337907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.